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CERVICAL CANCER
Approximately 1.6% of all women will develop cancer of the
cervix during their lifetime (4). Cervical cancer is the second
leading type of cancer in women and accounts for approxi-
mately one-sixth of all cancer deaths in females. In many ways,
cervical cancer behaves as a sexually transmitted disease. The
major risk factors associated with cervical cancer are the early
onset of sexual intercourse, multiple sexual partners, and/or
sexual contact with promiscuous partners (66, 94). The disease
is composed of several pathological stages ranging from cervi-
cal intraepithelial neoplasia (CIN) to invasive squamous car-
cinoma. Substantial evidence suggests that CIN is a precursor
of invasive cervical carcinoma (76, 88). Cytological and colpo-
scopic studies have determined that most initial neoplastic
events occur within the cervical squamous epithelium adjacent
to the endocervical epithelium (the squamocolumnar junction
or transformation zone [reviewed in reference 108]). At the
junction where columnar epithelium becomes squamous epi-
thelium, there is a temporary state of genetic imbalance that
renders the immature cells susceptible to neoplastic events. It
is believed that unique developmental aspects of the squamo-
columnar junction as well as exogenous factors are necessary
for induction of cervical carcinoma.
INVOLVEMENT OF HPV WITH CERVICAL CANCER
Certain human papillomavirus (HPV) types that are trans-
mitted primarily by sexual contact are commonly detected in
CIN and invasive carcinoma. Papillomaviruses are members of
the family Papovaviridae and contain a genome that is com-
posed of double-stranded DNA approximately 8 kb long (54)
(Fig. 1). HPV early (E) genes (E1 to E7) encode proteins
which regulate transcription, replication, or episomal mainte-
nance. The late (L) genes (L1 and L2) encode structural pro-
teins which are required to form a viral particle. More than 70
different types of HPV exist, with each type infecting either
cutaneous or squamous epithelium at defined anatomical lo-
cations. HPVs can be classified with respect to oncogenic po-
tential as either low, intermediate, or high risk. HPV-6 and
HPV-11 are found primarily in genital condylomata (44, 45)
and are rarely detected in cervical carcinomas; therefore, they
are regarded as low-risk viruses. HPV-31, HPV-33, and
HPV-35 are found in approximately 10% of cervical dysplasias,
primarily premalignant lesions (37), and are classified as inter-
mediate-risk types. HPV-16 and HPV-18 are found in biopsy
specimens of most invasive carcinomas (9, 20a, 28, 36, 44, 60),
and are considered high-risk types (9, 44, 75, 120, 122). In
cervical cancer cells, HPV DNA is frequently integrated with
cellular DNA, while benign lesions contain episomal viral
DNA (33). At the site of integration, cellular sequences are
frequently deleted and/or rearranged, but integration does not
appear to occur at specific cellular loci (85, 112). However,
integration generally disrupts two early viral genes, E1 and E2.
The E6 and E7 genes of high-risk HPVs are almost always
expressed in cervical cancer cells (74, 85) and can immortalize
primary human keratinocytes (33, 34, 65, 116; reviewed in
reference 28) or fibroblasts (23, 91). The E7 proteins of high-
risk HPVs bind to the retinoblastoma protein (RB), a tumor
suppressor gene product, with 10-fold-higher efficiency than do
E7 proteins of low-risk HPVs (99, 107). Deletion or inactiva-
tion of the gene encoding RB plays a crucial role in the devel-
opment of retinoblastoma (31). RB participates in regulating
the G1 phase of the cell cycle, presumably by interacting with
other regulatory proteins (71). For example, RB interacts with
(i) transcription factor E2F, thus inhibiting E2F-dependent
transcription (12, 52); (ii) transcription factors involved with
SP-1-dependent transcription, thus activating SP-1-dependent
transcription (67); (iii) transcription factor ATF-2, thus acti-
vating tumor growth factor b2 transcription (68); (iv) D cyclins
(30); and (v) c-Abl, thus blocking its tyrosine kinase activity
(113). In addition to binding to RB, E7 can trans-activate gene
expression (89). The E6 protein of high-risk HPVs binds to the
cellular tumor suppressor protein, p53, induces degradation of
p53 (96), and can trans-activate the adenovirus E2 promoter
(99). In response to DNA damage, p53 activates transcription
of a cyclin-dependent kinase inhibitor (Waf-1/CIP-1), which
blocks entry into S phase, thus allowing repair of DNA damage
(64, 87). In summary, the interactions between HPV oncogene
products E6 and E7 and tumor suppressor gene products p53* Phone: (402) 472-1890. Fax: (402) 472-9690.
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and RB, respectively, are essential for immortalization of hu-
man cells and development of cervical carcinoma.
RELATIONSHIP OF HSV-2 WITH CERVICAL CANCER
In addition to HPV, other factors are postulated to play a
role in the development of cervical cancer (reviewed in refer-
ence 21). These include smoking (8), human cytomegalovirus,
human herpesvirus 6 (27, 28), human immunodeficiency virus
(111), and HSV-2. HSV-2 is spread primarily by sexual contact,
and therefore the risk factors are similar to those of other
sexually transmitted diseases (105). A recent epidemiological
study suggested that a biological interaction between HSV-2
and HPV-16 or HPV-18 occurs during the development of
cervical carcinoma (53). This study also suggested that infec-
tion with both viruses is a significant risk but that infection with
one or the other is not nearly as significant. Several indepen-
dent epidemiological studies have also linked HSV-2 infections
to an increased incidence of cervical carcinoma (19, 25, 26, 66,
80, 81, 93; reviewed in references 21 and 36). Unfortunately,
these studies do not include the contribution by the risk asso-
ciated with HPV infection. In contrast, other studies found no
correlation between HSV-2 and cervical cancer (see, for ex-
ample, references 8, 20a, 24, 47, 60, 70, and 86). Some of the
negative studies may have minimized the risk factor because
women used as case controls were overmatched for sexual
activity. Furthermore, the use of immunoglobulin A rather
than immunoglobulin G as a marker for the presence of HSV-2
correlates with various stages of cervical cancer (18). In studies
that found no correlation of HSV-2 with cervical cancer, the
risk may have been underestimated if immunoglobulin G levels
were used to measure HSV infection. Although the epidemi-
ological studies do not conclusively demonstrate that HSV-2
plays a role in cervical cancer, there is evidence that HSV-2 has
the potential to be a risk factor associated with a subset of
cervical cancer cases.
Six of eight cervical cancer biopsy specimens that contained
HSV-2 DNA sequences also contained HPV DNA (25, 26).
Approximately 30% of genital tumors have DNA sequences
homologous to HSV-2 DNA, which can transform rodent or
human cells (25, 26). HSV-2 DNA sequences which have trans-
forming potential are contained in a BglII N or BamHI E
fragment (Fig. 2). In 29 of 55 neoplastic genital tissues, the
HSV-2 large subunit of ribonucleotide reductase (RRA),
which is encoded by the BamHI E fragment, was detected
by immunochemistry (25). However, this viral antigen was
not detected in normal tissue or in tumors at other sites. An
independent study also demonstrated that RRA is detectable
in more than 50% of cervical cancer biopsy specimens (3).
HSV-2 RNA can be detected in a higher proportion of CIN
than of squamous cell carcinoma, supporting the hypothesis
FIG. 1. Schematic of the HPV-16 genome, showing a restriction enzyme map
of the prototype HPV-16 genome and the location of open reading frames. The
organization of open reading frames in all high-risk-type HPV strains is similar.
FIG. 2. Location of mtrII and mtrIII within the HSV-2 genome. The positions of 486TF, mRNAs encoding RRA and RRB, RRA protein (140 kDa), and RRB
protein (38 kDa) are presented. Within the RRA protein, the location of the protein kinase domain (PK) is between amino acids 1 and 411 (14). The position of the
leucine zipper (L. Zip) is between amino acid 409 and 437 (72, 103). The catalytic site (Cat. Site) is in the C terminus of the protein (83).
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that HSV-2 is linked to the initiation of cervical carcinoma
(35). In contrast, HSV-2 RNA or DNA was not detected in
normal cervical tissue. Although HSV-2 may not be associated
with all cases of cervical cancer, there is molecular evidence
indicating that HSV-2 and HPV coinfections occur in cervical
cells and that the infected cells survive and may become neo-
plastic.
TRANSFORMING DOMAINS IN THE HSV-2 GENOME
Inactivated HSV-2 will alter the growth properties of rodent
or human cells, and after passage in culture, these cells can
form tumors in rodents (32, 73). Early experiments suggested
a ‘‘hit-and-run’’ mechanism since the continued presence of
virus is not required for transformation (38, 100). When inac-
tivated HSV-2 was topically applied to the mouse cervix, le-
sions similar to those seen in women with cervical cancer were
detected in approximately 60% of the animals (2, 115). Ap-
proximately 21% of these animals developed invasive cervical
carcinoma. No cancers were detected in control animals
treated with human or calf thymus DNA. Preimmunization of
animals with HSV-2 prevented the progression to carcinomas
(114). Two distinct and separate morphological transforming
regions (designated mtrII and mtrIII) have been identified in
the HSV-2 genome (38–41, 58, 59, 62) (Fig. 2). mtrII is con-
tained within the BglII N fragment, and mtrIII is contained
within the BglII C fragment. mtrII and mtrIII contain the genes
for the RR (77) small subunit (RRB) and large subunit
(RRA), respectively, suggesting that inappropriate expression
of this enzyme may play a role in transformation by altering
deoxynucleoside triphosphate pools.
mtrII
The BglII N fragment (mtrII) will induce neoplastic trans-
formation of established rodent cells (38, 39, 41) and human
keratinocytes immortalized with HPV-16 (29). The minimal
transforming fragment of mtrII is a 737-bp fragment that does
not contain the intact coding sequences for RRB. Further-
more, retention of mtrII is not consistently observed, implying
that it initiates transformation but is not required for mainte-
nance of the transformed phenotype. A stem-loop structure is
present within the minimal transforming fragment of mtrII,
and this structure has been implicated in the transformation
process (38). Although the stem-loop structure resembles
transposons of Drosophila melanogaster (P elements), the viral
stem-loop structure is not large enough to encode a transpo-
sition function, nor does it appear to be a classical insertion
sequence. mtrII can act as a mutagen (39), suggesting that it
can activate proto-oncogenes or inactivate tumor suppressor
genes. A plasmid rescued from rat cells transformed by mtrII
contains rat DNA flanked by mtrII DNA sequences (5), sug-
gesting that mtrII is capable of transducing rat DNA se-
quences. If the transduced rat DNA is hybridized to HSV
DNA, specific hybridization occurs with the HSV-2 BamHI E
fragment (contained within mtrIII [Fig. 2]). Interestingly, the
transduced rat DNA is frequently rearranged after transfor-
mation by mtrII and the transduced rat DNA induces neoplas-
tic transformation, suggesting that it contains a cellular onco-
gene. In summary, the ability of mtrII to induce mutations or
transduce cellular DNA sequences is required for initiating
neoplastic transformation but not maintaining the transformed
phenotype.
mtrIII
The BglII C fragment of HSV-2 (mtrIII) will induce multi-
step transformation of primary hamster cells (58). The left-
hand two-thirds of BglII-C can immortalize primary hamster
cells but does not immortalize primary human fibroblasts (23,
59), suggesting that the requirements for immortalizing ham-
ster cells are less stringent. The right-hand one-third, BamHI E
fragment, induces tumorigenic conversion of established cell
lines (59, 121). The minimal transforming region of BamHI-E
maps to a 486-bp PstI-SalI fragment (designated 486TF) or a
1.3-kb PstI fragment (PstI-C), which contains 486TF (Fig. 2) (1,
62). Plasmids containing mtrIII can cooperate with HPV-16 to
morphologically transform human cells (fibroblasts or kerati-
nocytes), and HSV-2 DNA sequences are retained in some
transformed cells (22, 23).
The only intact gene within the BamHI E fragment is RRA
(109) (Fig. 2). Deletion of the RRA gene prevents virus rep-
lication in animal models and restricts viral growth in arrested
cells (7, 10, 46, 57). Although RR enzymatic activity is ex-
pressed as an early enzyme, the RRA promoter has a cis-acting
motif (TAATGARAT), which is found in all immediate-early
genes of HSV (119). However, RRA RNA expression does not
readily occur in the absence of protein synthesis, suggesting
that it is not regulated as a typical immediate-early gene in
infected cells (50, 110). Interestingly, the RRA promoter can
be trans-activated by cellular proto-oncogenes (jun, fos, and
c-myc), the tumor suppressor gene RB, and the HPV E2 gene
(50, 117, 118). The RRA promoter contains two AP-1-binding
sites, which can be activated by jun-fos heterodimers (92), two
RB control elements, and a consensus E2-binding site (50, 92,
117). The RRA protein consists of at least three functional
domains (Fig. 2). Unlike any known mammalian RRA, the
N-terminal domain (amino acids 1 to 411) has serine/threo-
nine-specific protein kinase activity (14). Apparently, the pro-
tein kinase domain is a transduced cellular gene fragment
fused to the amino terminus of RRA (103). As with other
mammalian RRs, catalytic activity is contained at the C termi-
nus of RRA (83). Between the protein kinase domain and the
catalytic domain, a novel leucine zipper-like motif which facil-
itates subunit association and enzymatic activity is found (72,
102).
Does RRA play a role in neoplastic transformation? Inap-
propriate expression of RRA may lead to higher mutation
frequencies or unscheduled cell division. Although transient-
transfection assays suggest that HSV-2 RRA and RRB are not
mutagens (15), stable cell lines expressing mutant forms of
mammalian RRA have increased mutation frequency (11).
The HSV-2 RRA protein has been reported to have trans-
phosphorylating activity (14, 102), but HSV-1 RRA apparently
does not (17). A fraction of HSV-2-encoded RRA localizes to
plasma membranes, suggesting that it can function as a growth
factor receptor (14, 72). A recent report demonstrated that the
protein kinase domain of RRA phosphorylates and activates
ras (102), suggesting that this activity is important for neoplas-
tic transformation. If PstI-C (which contains 486TF and the
protein kinase domain of RRA) is placed in a mammalian
expression vector and transformation ability in rodent cells is
compared with that of PstI-C in a plasmid lacking mammalian
regulatory signals, the efficiency of transformation is increased
(1). Furthermore, an RRA temperature-sensitive mutant of
HSV-2, containing mutations in the protein kinase domain of
RRA, does not morphologically transform established rodent
cells as efficiently as wild-type HSV-2 does (101), suggesting
that the protein kinase domain enhances transformation. The
amino-terminal domain of HSV-2 has only 38% similarity to
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that of HSV-1, but the remainder of the protein has approxi-
mately 93% similarity (83), adding credence to the importance
of the protein kinase domain in neoplastic transformation.
Given the importance of ras in signal transduction and onco-
genic transformation (79), the finding that HSV-2 RRA acti-
vates ras is an attractive model to explain the mechanism by
which mtrIII induces neoplastic transformation.
Other studies have indicated that 486TF alone (which does
not contain the protein kinase domain of RRA) can induce
tumorigenic transformation of Rat-2 cells or induce altered
growth of human fibroblasts or keratinocytes (22, 23, 62). In
transient-transfection assays, 486TF is a complex transcrip-
tional regulatory element composed of two distinct promoters,
a transcriptional silencer, and a distal activating element (42,
61, 63). Novel proteins in HSV-2-transformed cells specifically
bind to 486TF, suggesting that transformed cells contain novel
transcription factors. Transcriptional regulatory motifs within
486TF may alter cellular gene expression following integration
and may consequently induce transformation. Whether pro-
moter elements in 486TF are utilized to synthesize novel viral
transcripts which are necessary for morphological transforma-
tion is currently not known. Like mtrII, 486TF contains repet-
itive DNA sequences which can be folded into relatively stable
hairpin structures (62, 63). Nuclear proteins specifically bind to
sequences within these structures (63), suggesting that the
structures are stabilized by cellular proteins. Perhaps stem-
loop structures in 486TF mediate neoplastic transformation by
facilitating recombination or altering expression of growth-
regulatory genes. Although the protein kinase activity of RRA
enhances neoplastic transformation, the fact that 486TF has
transforming activity suggests that two transforming domains
are present in BamHI-E.
INTERPLAY BETWEEN HSV-2 AND HIGH-RISK HPV
Two studies have examined the ability of mtrIII to cooperate
with HPV-16 or HPV-18 to transform human fibroblasts or
keratinocytes (22, 23). If primary human fibroblasts are trans-
fected with a retrovirus shuttle vector containing HPV-16 and
fragments derived from mtrIII, aneuploidy occurs in nearly
90% of the transformed cell lines and the cells exhibit anchor-
age-independent growth but do not form tumors in nu/nu mice
(22). Transformed cells consistently retain HSV-2 DNA se-
quences as judged by PCR analysis. As expected, immortalized
cell lines were established after primary human fibroblasts
were transfected with HPV-16 alone. Aneuploidy was detected
in only 10% of the cell lines transfected with HPV-16, and
these cells do not grow efficiently in soft agar. For these stud-
ies, primary human cells were obtained from two patients:
gingival fibroblasts from a ‘‘normal’’ adult (N16), and gingival
fibroblasts from an epileptic patient treated with an anticon-
vulsant drug, phenytoin (R30). One side effect of phenytoin is
that it induces gingival overgrowth, thus making it necessary
to surgically remove the overgrown tissue. Karyotype analysis
revealed that R30 cells contained a stable translocation be-
tween chromosomes 8 and 18. Since the human proto-onco-
gene c-myc is present on chromosome 8 (82), the status of
c-myc in R30 cells was examined. Higher steady-state levels of
c-myc RNA were observed in R30 cells than in N16 cells, but
the genomic organization appeared normal. Stable cell lines of
R30 but not N16 were efficiently established when transfected
with HPV-16 or HPV-16/mtrIII, implying that c-myc expres-
sion facilitated establishment of these cell lines. Amplification
of c-myc has also been suggested to play a role in cervical
cancer (84).
When human keratinocytes immortalized with HPV-16
(FEPL) or HPV-18 (FEA) were transfected with plasmids
containing mtrIII, the resulting cell lines grew to higher sat-
uration densities (22). FEPL but not FEA cells transfected
with mtrIII developed into benign lesions in nu/numice. These
lesions were macroscopic and consisted of squamous epithelial
cells secreting keratin. Although the organization of c-Myc and
p53 was not altered after introduction of mtrIII into FEA and
FEPL cells, rearrangements of HPV-18 DNA were frequently
observed in FEA cells. FEA and FEPL cells transfected with
mtrIII did not express higher steady-state levels of HPV
mRNAs which encode E6 or E7 relative to their parental
counterparts, suggesting that changes in growth properties
were not merely the result of higher levels of E6 or E7 expres-
sion.
A plasmid containing mtrII can convert genital epithelial
cells containing integrated HPV-16 sequences into tumori-
genic squamous cell carcinomas (29). The tumors were aneu-
ploid with a near triploid number and had five copies of chro-
mosomes 2 and 9. Furthermore, several marker chromosomes
were derived from chromosomes 5, 7, and 16. Upon prolonged
passage, the HSV-2 DNA sequences were ‘‘lost’’ as judged by
Southern blotting studies. However, oncogenic potential was
not lost, thus supporting the role that mtrII is required for
initiating oncogenic transformation but not for maintaining the
transformed phenotype. The notion that high-risk HPV types
are necessary but not sufficient for cervical cancer is supported
by these studies. Although these studies demonstrate that
HSV-2 transforming fragments (mtrII and mtrIII) can coop-
erate with HPV to transform human cells, it will be necessary
to corroborate these findings with studies that compare the risk
of cervical cancer or invasiveness of disease in women exposed
to both viruses with the risk in women exposed to one virus.
ABILITY OF HSV TO INDUCE MUTATIONS, GENOMIC
REARRANGEMENTS, OR ACTIVATION OF
ONCOGENES AS A MECHANISM FOR
INITIATION OF TUMORIGENESIS
HSV infection can induce chromosomal breaks (48, 106),
amplification of chromosomal DNA (97), and formation of
double minute chromosomes (13, 40, 51). Furthermore, infec-
tion of a simian virus 40-transformed hamster cell line induces
up to 500-fold amplification of integrated simian virus 40 DNA
sequences (43). Flanking cellular sequences are also amplified,
and simian virus 40-encoded T antigen is necessary for ampli-
fication. Amplification of HPV-18 DNA sequences also occurs
in HeLa cells after infection by HSV-2 (6), suggesting that
HSV infections induce cellular DNA synthesis. The ability of
HSV-2 to induce unscheduled DNA synthesis in several cer-
vical cancer cell lines (HeLa, CaSki, C-33A, and SiHa) was
examined (69). Flow-cytometric analysis in all of the cell lines
indicated increases in the proportion of G1- and S-phase cells
which were synthesizing DNA. In HeLa cells, this was an early
event after infection, but in C-33A and SiHa cells, it was a late
event. If HSV-2 replication is blocked with phosphonoformate,
virus-induced changes are abolished in HeLa cells but not in
C-33A or SiHa cells, suggesting that unscheduled DNA repli-
cation is cell type dependent. Replication of episomal DNA or
unscheduled DNA synthesis (repair replication of chromo-
somal DNA) is necessary for DNA amplification to occur
(104), suggesting that these two processes are linked. Six HSV-
encoded genes are involved in amplification of episomal DNA
(51): UL5, UL8, UL52 (components of the viral helicase-pri-
mase complex which is essential for viral DNA replication),
UL29 (single-stranded DNA-binding protein necessary for
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DNA replication), UL30 (DNA polymerase), and UL42 (sub-
unit of DNA polymerase). In summary, these studies indicated
that an HSV infection induces cell cycle progression which
ultimately leads to amplification of chromosomes.
Infection of permissive cells with UV-irradiated HSV-1 (98)
or nonpermissive cells with HSV-2 (90) increases the mutation
frequency of the hypoxanthine-guanine phosphoribosyltrans-
ferase gene. Mutation frequencies are similar to those pro-
duced by the chemical carcinogen 4-nitroquinoline-1-oxide,
and DNA damage is followed by cellular DNA repair (98). The
mutagenic properties of HSV were extended by using a plas-
mid-based gene (supF), which is located on the shuttle vector
pZ189. This system allows one to identify where specific mu-
tations are introduced into the supF gene. Although the mu-
tagenic effects of HSV were primarily point mutations typically
induced by chemical carcinogens, deletion and insertion mu-
tations were also observed (56). Increases in mutagenesis of
pZ189 occur early in infection but do not require functional
RRA activity, RRB activity, or viral gene expression (15).
Penetration of virus into the cell is required, suggesting that a
viral component mediates mutagenesis. Although the viral
gene(s) necessary for mutagenesis has not been identified, it is
clear that entry of a noninfectious HSV particle into a cell
could lead to mutagenesis but not death of the cell. The ability
of HSV to act as a potent mutagen and induce DNA amplifi-
cation may have important ramifications with respect to its role
in cervical cancer, because cervical cancer biopsy specimens
frequently have abnormalities in chromosome 11 (49) or chro-
mosome 17 (95).
POTENTIAL INTERACTIONS BETWEEN HSV-2 AND
HPV DURING INDUCTION OF CERVICAL CANCER
It would be easy to dismiss HSV-2 as a cofactor in the
development of cervical cancer, because it is not a prototype
DNA tumor virus. Unlike simian virus 40, HPV, or adenovi-
ruses, HSV-2 does not apparently encode a viral oncogene
which disarms p53 and/or RB. If HSV-2 plays a direct role in
cervical cancer, it is reasonable to hypothesize that some in-
fected cells survive and that a subset of viral genes are ex-
pressed during a persistent or abortive infection. Alternate
sites of latent or persistent infections do occur for HSV-2 in
addition to latent infections in sensory neurons (16; reviewed
in reference 20), supporting the concept that persistent or
latent infections occur in cervical tissue. A potential model for
the involvement of HSV-2 in cervical carcinoma is outlined in
Fig. 3. HSV-2 infection of cervical epithelial cells (normal or
HPV1) leads to mutations and/or rearrangements of cellular
genes which have growth regulatory function. The neoplastic
properties of mtrII and mtrIII may also contribute to altered
growth properties. If cells are HPV1 prior to HSV-2 infection,
mutagenesis would be more detrimental, because p53 is se-
questered and degraded by E6 (96). Consequently, p53 would
not restrict cell cycle progression after DNA damage (64, 87),
suggesting that HPV1 cells that are mutagenized by HSV-2
continue to proliferate. Since HPV infections are frequently
associated with CIN and cervical cancer (9, 20a, 28, 36, 44, 60),
it does not seem likely that HSV-2 frequently induces cervical
cancer by itself. However, it is possible that novel growth fac-
tors are produced after cervical cells (HPV1 or HPV2) are
infected by HSV-2, resulting in proliferation of adjacent cells
latently infected with HPV. Considering that HPV morpho-
genesis is coupled to epithelial cell differentiation and that
HPV oncogene expression (E6 and E7) is higher in undiffer-
entiated cells (55, 78), development of cervical pathologic
changes would be favored after HSV-2-induced mutagenesis.
There is no doubt that cervical cells can survive infection by
HPV plus HSV-2 and then progress to cervical cancer, because
DNA from both viruses has been detected in cervical cancer
biopsy specimens (25, 26). The observation that HSV mu-
tagenesis is an early event during a lytic infection cycle (15, 56)
suggests that cervical cells can be mutated during a nonpro-
ductive infection or even by a defective virus genome which is
packaged. In summary, the most logical way that HSV-2 par-
ticipates as a cofactor in progression of CIN to cervical carci-
noma is to induce DNA damage or chromosomal abnormali-
ties in cervical epithelial cells that are latently infected with
HPV.
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